392 related articles for article (PubMed ID: 25156567)
1. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.
Franco J; Witkiewicz AK; Knudsen ES
Oncotarget; 2014 Aug; 5(15):6512-25. PubMed ID: 25156567
[TBL] [Abstract][Full Text] [Related]
2. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
Witkiewicz AK; Borja NA; Franco J; Brody JR; Yeo CJ; Mansour J; Choti MA; McCue P; Knudsen ES
Oncotarget; 2015 Jun; 6(18):15788-801. PubMed ID: 26158861
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.
Salvador-Barbero B; Álvarez-Fernández M; Zapatero-Solana E; El Bakkali A; Menéndez MDC; López-Casas PP; Di Domenico T; Xie T; VanArsdale T; Shields DJ; Hidalgo M; Malumbres M
Cancer Cell; 2020 Mar; 37(3):340-353.e6. PubMed ID: 32109375
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.
Franco J; Balaji U; Freinkman E; Witkiewicz AK; Knudsen ES
Cell Rep; 2016 Feb; 14(5):979-990. PubMed ID: 26804906
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer.
Knudsen ES; Kumarasamy V; Ruiz A; Sivinski J; Chung S; Grant A; Vail P; Chauhan SS; Jie T; Riall TS; Witkiewicz AK
Oncogene; 2019 May; 38(18):3355-3370. PubMed ID: 30696953
[TBL] [Abstract][Full Text] [Related]
6. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma.
Zhang B; Li D; Jin X; Zhang K
Int J Biochem Cell Biol; 2020 Nov; 128():105859. PubMed ID: 32987196
[TBL] [Abstract][Full Text] [Related]
7. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
Knudsen ES; Witkiewicz AK
Oncotarget; 2016 Oct; 7(43):69111-69123. PubMed ID: 27564114
[TBL] [Abstract][Full Text] [Related]
8. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.
Chou A; Froio D; Nagrial AM; Parkin A; Murphy KJ; Chin VT; Wohl D; Steinmann A; Stark R; Drury A; Walters SN; Vennin C; Burgess A; Pinese M; Chantrill LA; Cowley MJ; Molloy TJ; ; Waddell N; Johns A; Grimmond SM; Chang DK; Biankin AV; Sansom OJ; Morton JP; Grey ST; Cox TR; Turchini J; Samra J; Clarke SJ; Timpson P; Gill AJ; Pajic M
Gut; 2018 Dec; 67(12):2142-2155. PubMed ID: 29080858
[TBL] [Abstract][Full Text] [Related]
9. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.
Maust JD; Frankowski-McGregor CL; Bankhead A; Simeone DM; Sebolt-Leopold JS
Mol Cancer Ther; 2018 Dec; 17(12):2495-2506. PubMed ID: 30254182
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract][Full Text] [Related]
12. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
[TBL] [Abstract][Full Text] [Related]
15. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
16. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
[No Abstract] [Full Text] [Related]
17. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells.
Liu F; Korc M
Mol Cancer Ther; 2012 Oct; 11(10):2138-48. PubMed ID: 22869556
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer.
Kumarasamy V; Ruiz A; Nambiar R; Witkiewicz AK; Knudsen ES
Oncogene; 2020 Feb; 39(9):1831-1845. PubMed ID: 31745297
[TBL] [Abstract][Full Text] [Related]
19. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
20. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]